Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Acquired by Cavalier Investments LLC

Cavalier Investments LLC increased its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 4.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,785 shares of the biopharmaceutical company’s stock after buying an additional 144 shares during the quarter. Cavalier Investments LLC’s holdings in Madrigal Pharmaceuticals were worth $1,168,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Los Angeles Capital Management LLC acquired a new stake in shares of Madrigal Pharmaceuticals in the fourth quarter valued at $849,000. Handelsbanken Fonder AB lifted its holdings in shares of Madrigal Pharmaceuticals by 0.9% during the fourth quarter. Handelsbanken Fonder AB now owns 32,800 shares of the biopharmaceutical company’s stock valued at $10,121,000 after purchasing an additional 300 shares during the last quarter. Kornitzer Capital Management Inc. KS purchased a new stake in shares of Madrigal Pharmaceuticals during the fourth quarter valued at $4,554,000. D.A. Davidson & CO. purchased a new stake in shares of Madrigal Pharmaceuticals during the fourth quarter valued at $221,000. Finally, Sanctuary Advisors LLC lifted its holdings in shares of Madrigal Pharmaceuticals by 5.2% during the fourth quarter. Sanctuary Advisors LLC now owns 1,247 shares of the biopharmaceutical company’s stock valued at $422,000 after purchasing an additional 62 shares during the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Madrigal Pharmaceuticals Stock Performance

Shares of MDGL stock opened at $309.49 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. Madrigal Pharmaceuticals, Inc. has a fifty-two week low of $189.00 and a fifty-two week high of $368.29. The stock’s 50-day moving average is $320.09 and its two-hundred day moving average is $282.67. The firm has a market cap of $6.75 billion, a P/E ratio of -12.34 and a beta of -0.38.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. UBS Group upped their target price on Madrigal Pharmaceuticals from $411.00 to $441.00 and gave the company a “buy” rating in a report on Friday, November 1st. HC Wainwright upped their target price on Madrigal Pharmaceuticals from $390.00 to $400.00 and gave the company a “buy” rating in a report on Tuesday, January 14th. JMP Securities reaffirmed a “market outperform” rating and set a $427.00 target price on shares of Madrigal Pharmaceuticals in a report on Friday, January 10th. Cantor Fitzgerald reissued a “neutral” rating on shares of Madrigal Pharmaceuticals in a research note on Wednesday, November 20th. Finally, B. Riley increased their price objective on Madrigal Pharmaceuticals from $194.00 to $236.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $351.67.

Insiders Place Their Bets

In other news, VP Robert E. Waltermire sold 442 shares of the stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $273.41, for a total transaction of $120,847.22. Following the transaction, the vice president now owns 5,058 shares of the company’s stock, valued at approximately $1,382,907.78. This represents a 8.04 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO William John Sibold sold 1,584 shares of the stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $335.24, for a total value of $531,020.16. Following the transaction, the chief executive officer now directly owns 54,303 shares in the company, valued at approximately $18,204,537.72. This represents a 2.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 8,690 shares of company stock valued at $2,692,601 in the last three months. Insiders own 22.80% of the company’s stock.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.